title: 2D-DIGE proteomic analysis of changes in estrogen/progesterone-induced rat breast hyperplasia upon treatment with the Mongolian remedy RuXian-I.
abstract: RuXian-I has traditionally been used as a remedy for breast hyperplasia in the Inner Mongolia Autonomous Region of China. As a first step toward the investigation of biomarkers associated with RuXian-I treatment, a proteome-wide analysis of rat breast tissue was conducted. First, rat breast hyperplasia was induced by injection of estradiol and progesterone. After treatment with RuXian-I, there is a marked decrease in the hyperplasia, as can be shown by decreases in the nipple diameter and the pathological changes in breast. Subsequently, we used an approach that integrates size-based 2D-DIGE, MALDI-TOF/TOF-MS, and bioinformatics to analyze data from the control group, the model group and the RuXian-I treatment group. Using this approach, seventeen affected proteins were identified. Among these, 15 (including annexin A1, annexin A2, superoxide dismutase [Mn], peroxiredoxin-1, translationally-controlled tumor protein and a B-crystallin) were significantly up-regulated in the model group and down-regulated upon treatment with RuXian-I, and two (Tpil protein and myosin-4) have the opposite change trend. The expression of annexin A1 was confirmed using immunohistochemistry. The expression of superoxide dismutase (SOD) activity was confirmed biochemically. These results indicated that RuXian-I treats rat breast hyperplasia through regulation of cell cycle, immune system, metabolic, signal transduction, etc. The differential expressions of these proteins (annexin A1, superoxide dismutase [Mn], alpha B-crystallins and translationally controlled tumor protein, among others) were associated with occurrence and metastasis of breast cancer. These findings might provide not only far-reaching valuable insights into the mechanism of RuXian-I action, but also leads for prognosis and diagnosis of breast hyperplasia and breast cancer.
authors.affiliation: Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
authors.forename: Zhong-Chao
authors.initials: ZC
authors.lastname: Wang
authors.forename: Du
authors.initials: D
authors.lastname: E
authors.forename: De-Ligen
authors.initials: DL
authors.lastname: Batu
authors.forename: Ya-Latu
authors.initials: YL
authors.lastname: Saixi
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.forename: Li-Qun
authors.initials: LQ
authors.lastname: Ren
mesh_terms: D000818:Animals; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006965:Hyperplasia / Q000139:chemically induced*; D008321:Mammary Glands, Animal / Q000187:drug effects* / Q000473:pathology; D011374:Progesterone / Q000633:toxicity*; D040901:Proteomics; D051381:Rats; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D004365:Drugs, Chinese Herbal; D004967:Estrogens; C533634:ruxian I; D011374:Progesterone